Congressional Inquiry Into FDA Combo Product Policy Needed – Consultant
This article was originally published in The Gray Sheet
Executive Summary
R. Sheridan Consulting is urging Congress to review FDA's criteria for determining whether a combination product should be regulated as a drug or a device